Enteral |
|
|
|
|
Oral (per os) |
Along gastrointestinal tract |
Ingestible gastric resident systems for antimalarials and antiretrovirals6 7
|
Non-invasive.
Can be self-administered.
Preferred by patients.
|
Non-adherence due to frequent dosing for high pill burden of TB treatment.
Chemical environment is harsh.
Degraded by first pass-metabolism.
|
Solid lipid nanoparticles of TB treatment9
|
Paediatric dispersible tablets for Coartem and delaminid16 17
|
Sublingual or buccal |
Surfaces in the mouth |
Metered sublingual spray of artemether (ArTiMist) for children18
|
Non-invasive.
Can be self-administered.
Rapid absorption.
Avoids first-pass metabolism.
|
Low surface area for absorption which limits dose and may not be in line with gram-level dosing of TB treatment.
Bitter taste of drugs.
Prone to irritation of oral mucosa.
|
Rectal |
Rectal mucosa |
Rectal artesunate suppositories for the prereferral management of severe malaria19
|
Useful for unconscious patients and children.
No need to taste-mask drug.
Partial avoidance of first-pass metabolism.
|
Absorption can be slow or erratic.
Frequent application to match gram-level dosing of TB treatment.
Prone to irritation of rectal mucosa.
|
Parental |
|
|
|
|
Intravenous |
Veins, systemic bioavailable |
Artemisinin nanoformulation20
|
Achieves 100% bioavailability.
Reproducible.
|
Invasive.
Requires trained personnel.
Prone to infection.
Frequent injections to match gram-level dosing of TB treatment.
|
Intramuscular |
Skeletal muscle |
Nanoparticles of rilpivirine and cabotegravir for HIV treatment21
|
Rapid absorption.
Avoids first-pass metabolism.
|
Invasive.
Limited volume for injection, so may not match gram-level dosing of TB treatment.
Risk of nerve damage.
|
|
|
Atovaquone solid drug nanoparticles for malaria prophylaxis22
|
Subcutaneous |
Into tissue between dermis and muscle |
Ultra-long-acting dolutegravir implant for HIV treatment and prevention23
|
Slow absorption and distribution compared with intramuscular.
Avoids first-pass metabolism.
|
Invasive.
Limited volume for injection, so may not match gram-level dosing of TB treatment.
Risk of tissue damage.
|
Nanochannel implant with refillable feature for delivery of tenofavir diphosphate24
|
Intradermal |
Into dermis layer |
Intradermal injections of HIV DNA vaccines using needle-free injector25
|
Faster absorption and distribution compared with subcutaneous.
Avoids first-pass metabolism.
Higher immune responses for vaccinations.
|
Invasive.
Limited volume for injection, so may not match gram-level dosing of TB treatment.
Risk of tissue damage.
|
Intrathecal |
Into cerebrospinal fluid |
Intrathecal administration of isoniazid for TB meningitis treatment26
|
Bypasses blood–brain barrier.
Local effect on meninges or cerebrospinal axis.
|
Invasive.
Limited volume for injection, so may not match gram-level dosing of TB treatment.
Risk of tissue damage.
|
Intra-articular |
Into joint space |
Intra-articular streptomycin in tuberculosis of the knee27
|
Avoids first-pass metabolism.
Local effect on joint.
|
Invasive.
Limited volume for injection, so may not match gram-level dosing of TB treatment.
Risk of tissue damage.
|
Inhalation |
Mucosal surfaces for the lung |
Nebulised solid lipid nanoparticles for TB treatment10
|
Non-invasive.
Large surface area for absorption.
Avoids first-pass metabolism.
Targets where TB bacteria reside.
|
Variability in dosing depends on patient technique.
Requires portable, cheap and easy to operate devices for administration.
Frequent inhalation to be compatible with gram-level dosing of TB treatment.
|
Nano microparticle vaccine formulation for TB28
|
Transdermal |
Through skin |
Film of HIV inhibitor IQP-041029
|
Non-invasive.
Can be self-administered.
Avoids first-pass metabolism.
|
Transport barriers for many drugs.
Slow absorption.
May require frequent administration or very large patch to match gram-level dosing of TB.
|
|
|
Solid dispersions of artemisinin for malaria treatment30
|
Topical: ocular, nasal, skin |
At site of application |
Topical treatment of cutaneous TB using oil nanoemulsions31
|
Non-invasive.
Can be self-administered.
Rapid absorption.
Local effect, so avoids side effects.
|
Transport barriers for many drugs.
May require frequent administration to match gram-level dosing of TB.
|
Intravaginal |
Mucosal surfaces lining the vagina |
Monthly vaginal rings for dapivirine, an HIV drug32
|
Reduce frequency of dosing.
Avoids first-pass metabolism.
Dense network of blood vessels in vagina, so ideal for systemic drug absorption.
|
Invasive.
Requires trained personnel.
Implants may require frequent dosing to match gram-level dosing of TB treatment.
|
Topical tenofovir disoproxil fumarate nanoparticles33
|